TRDA
insider transactionsEntrada Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-38.4K
5.0K buy · 43.4K sell
Net value · 90d
-$631.8K
$29.3K in · $661.1K out
Sentiment · 90d
Net selling
4% buying · 96% selling
Open-market trades · 90d
4
5.0K buy · 43.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director, 10% Owner
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Buy·P
Director
$29.3K
5.0K sh · $5.86
Own New
-
Sell·S
President, Research & Develop. · 10b5-1
$398.8K
25.9K sh · $15.39
Own -11%
-
Exercise·M
Nathan J Dowden KEY
President & COO · 10b5-1
$0
15.0K sh
Own +43%
-
Sell·S
Nathan J Dowden KEY
President & COO · 10b5-1
$230.0K
15.0K sh · $15.33
Own -7%
-
Exercise·M
Nathan J Dowden KEY
President & COO · 10b5-1
$26.1K
15.0K sh · $1.74
Own +8%
-
Sell·S
Chief Financial Officer · 10b5-1
$32.4K
2.5K sh · $12.95
Own -2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Maha Radhakrishnan | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Kush Parmar | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Peter S Kim | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Mary Thistle | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Bernhardt G Zeiher | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Gina Chapman | Grant A | 19.0K | $0 |
| May 20, 2026 | Bernhardt G Zeiher | Buy P | 5.0K | $29.3K |
| May 4, 2026 | Natarajan Sethuraman KEY 10b5-1 | Sell S | 25.9K | $398.8K |
| May 4, 2026 | Nathan J Dowden KEY 10b5-1 | Exercise M | 15.0K | $0 |
| May 4, 2026 | Nathan J Dowden KEY 10b5-1 | Sell S | 15.0K | $230.0K |
| May 4, 2026 | Nathan J Dowden KEY 10b5-1 | Exercise M | 15.0K | $26.1K |
| Apr 1, 2026 | Kory James Wentworth KEY 10b5-1 | Sell S | 2.5K | $32.4K |
About TRDA insider trading
This page tracks insider transactions for Entrada Therapeutics, Inc. (TRDA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.